Laurie A. Farrell

Laurie A. Farrell

Auto-generated profile, based on publicly available information

Laurie A. Farrell

CardioVascular Institute, Beth Israel Deaconess Medical Center, Boston, MA (A.L.B., A. Ariza, M.U., J.M.N.-P., C.C., Y.P., S.A., A.N.R.D., J.B., L.F., J.N.U., C.W.H., M.L., R.G., A. Asnani)

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 December 2022 in Science Advances
Verified
Journal Article
Open access
JLJing Liu
Jing Liu
SLSarah Lane
Sarah Lane
RLRahul Lall
Rahul Lall
MRMichele Russo
Michele Russo
LFLaurie Farrell
Laurie Farrell
AAAarti Asnani
Aarti Asnani
Anthracyclines such as doxorubicin (Dox) are effective chemotherapies, but their use is limited by cardiac toxicity. We hypothesized that plasma proteomics in women with breast cancer could identify new mechanisms of anthracycline cardiac toxicity. We measured changes in 1317 proteins in anthracycline-treated patients ( n = 30) and replicated key findings in a second cohort ( n = 31). An increase in the heme-binding protein hemopexin (Hpx) 3 months after anthracycline initiation was associated with cardiac toxicity by echocardiography. To assess the functional role of Hpx, we administered Hpx to wild-type (WT) mice treated with Dox and observed improved cardiac function. Conversely, Hpx −/− mice demonstrated increased Dox cardiac toxicity compared to WT mice. Initial mechanistic studies indicate that Hpx is likely transported to the heart by circulating monocytes/macrophages and that Hpx may mitigate Dox-induced ferroptosis to confer cardioprotection. Together, these observations suggest that Hpx induction represents a compensatory response during Dox treatment.

19 June 2023 in Molecular & Cellular Proteomics
Verified
Journal Article
Open access
MMMichael Y. Mi
Michael Y. Mi
JBJacob L. Barber
Jacob L. Barber
PRPrashant Rao
Prashant Rao
LFLaurie A. Farrell
Laurie A. Farrell
MSMark A. Sarzynski
Mark A. Sarzynski
RGRobert E. Gerszten
Robert E. Gerszten
Regular exercise has many favorable effects on human health, which may be mediated in part by the release of circulating bioactive factors during each bout of exercise. Limited data exist regarding the kinetic responses of plasma proteins during and after acute exercise. Proteomic profiling of 4163 proteins was performed using a large-scale, affinity-based platform in 75 middle-aged adults who were referred for treadmill exercise stress testing. Plasma proteins were quantified at baseline, peak exercise, and 1-h postexercise, and those with significant changes at both exercise timepoints were further examined for their associations with cardiometabolic traits and change with aerobic exercise training in the Health, Risk Factors, Exercise Training and Genetics Family Study, a 20-week exercise intervention study. A total of 765 proteins changed (false discovery rate < 0.05) at peak exercise compared to baseline, and 128 proteins changed (false discovery rate < 0.05) at 1-h postexercise. The 56 proteins that changed at both timepoints included midkine, brain-derived neurotrophic factor, metalloproteinase inhibitor 4, and coiled-coil domain-containing protein 126 and were enriched for secreted proteins. The majority had concordant direction of change at both timepoints. Across all proteins assayed, gene set enrichment analysis showed increased abundance of coagulation-related proteins at 1-h postexercise. Forty-five proteins were associated with at least one measure of adiposity, lipids, glucose homeostasis, or cardiorespiratory fitness in Health, Risk Factors, Exercise Training and Genetics Family Study, and 20 proteins changed with aerobic exercise training. We identified hundreds of novel proteins that change during acute exercise, most of which resolved by 1 h into recovery. Proteins with sustained changes during exercise and recovery may be of particular interest as circulating biomarkers and pathways for further investigation in cardiometabolic diseases. These data will contribute to a biochemical roadmap of acute exercise that will be publicly available for the entire scientific community.

21 September 2020 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
DNDebby Ngo
Debby Ngo
DWDonghai Wen
Donghai Wen
YGYan Gao
Yan Gao
MKMichelle J. Keyes
Michelle J. Keyes
EDErika R. Drury
Erika R. Drury
EREugene P. Rhee
Eugene P. Rhee
In addition to their fundamental role in clearance, the kidneys release select molecules into the circulation, but whether any of these anabolic functions provides insight on kidney health is unknown. Using aptamer-based proteomics, we characterized arterial (A)-to-renal venous (V) gradients for >1,300 proteins in 22 individuals who underwent invasive sampling. Although most of the proteins that changed significantly decreased from A to V, consistent with renal clearance, several were found to increase, the most significant of which was testican-2. To assess the clinical implications of these physiologic findings, we examined proteomic data in the Jackson Heart Study (JHS), an African-American cohort (n = 1,928), with replication in the Framingham Heart Study (FHS), a White cohort (n = 1,621). In both populations, testican-2 had a strong, positive correlation with estimated glomerular filtration rate (eGFR). In addition, higher baseline testican-2 levels were associated with a lower rate of eGFR decline in models adjusted for age, gender, hypertension, type 2 diabetes, body mass index, baseline eGFR, and albuminuria. Glomerular expression of testican-2 in human kidneys was demonstrated by immunohistochemistry, immunofluorescence, and electron microscopy, while single-cell RNA sequencing of human kidneys showed expression of the cognate gene, SPOCK2, exclusively in podocytes. In vitro, testican-2 increased glomerular endothelial tube formation and motility, raising the possibility that its secretion has a functional role within the glomerulus. Taken together, our findings identify testican-2 as a podocyte-derived biomarker of kidney health and prognosis. Significance All existing blood biomarkers of kidney function such as creatinine and cystatin C undergo renal clearance and are thus inversely correlated with estimated glomerular filtrate rate (eGFR). Using a proteomic approach, we highlight the renal release of testican-2 among individuals undergoing invasive catheterization and show that higher blood testican-2 levels are associated with higher eGFR and slower rate of subsequent eGFR decline in two large racially diverse cohorts. In conjunction with microscopy and single-cell RNA sequencing of human kidney samples, these studies advance the concept that a protein released by the podocyte can provide insight into the kidney’s health and prognosis. Cell-based studies also raise the possibility that this protein has functional effects on neighboring glomerular endothelial cells.

19 June 2006 in European Journal of Neuroscience
Verified
Journal Article
Closed access
PDF file
GSG. Sadri‐Vakili
G. Sadri‐Vakili
AMA. S. Menon
A. S. Menon
LFL. A. Farrell
L. A. Farrell
CKC. E. Keller‐McGandy
C. E. Keller‐McGandy
ICI. Cantuti‐Castelvetri
I. Cantuti‐Castelvetri
JCJ.‐H. J. Cha
J.‐H. J. Cha

1 August 2025 in Circulation: Genomic and Precision Medicine
Verified
Journal Article
Closed access
UTUsman A. Tahir
Usman A. Tahir
DRDaniel Reichart
Daniel Reichart
APAnisha Purohit
Anisha Purohit
JBJacob L. Barber
Jacob L. Barber
GTGaurav Tiwari
Gaurav Tiwari
NLNeal K. Lakdawala
Neal K. Lakdawala
BACKGROUND: Pathogenic variants in the lamin A/C ( LMNA ) gene cause an aggressive form of dilated cardiomyopathy (DCM), marked by higher rates of advanced conduction disease, malignant ventricular tachyarrhythmias, and advanced heart failure compared with other causes of nonischemic cardiomyopathy. However, the mechanisms that drive the development and progression of LMNA DCM are incompletely understood. METHODS: To identify proteins and biological pathways associated with likely pathogenic/pathogenic LMNA variants, we measured ≈3000 plasma proteins using the OLINK platform in a genetic DCM cohort consisting of LMNA (n=41) and sarcomeric (n=18) DCM, along with phenotype-negative individuals from family-based cascade screening (n=55) with ( LMNA , n=16; sarcomere, n=12) or without the family variant (genotype negative, n=27). RESULTS: We identified several novel proteins associated with LMNA DCM compared with sarcomeric DCM, including EDA2R (ectodysplasin A2 receptor; per log2 fold change in relative protein abundance, β=3.0; P =4×10 − ³) and MYL4 (myosin light chain 4; β=2.32; P =5×10 − ³). Among the proteins associated with LMNA DCM, 26 showed concordant differential gene expression from single-cell sequencing in cardiomyocytes from myocardial biopsies in advanced LMNA heart failure compared with control hearts (false discovery rate, <5%). We performed principal component analyses on these 26 proteins to identify proteomic signatures of LMNA DCM and found the first principal component to be associated with left ventricular ejection fraction and complete heart block in the LMNA DCM cohort. Six proteins—EDA2R, MYL4, CRIM1 (cysteine-rich transmembrane bone morphogenetic protein regulator 1), TPR (translocated promoter region), FSTL3 (follistatin-like 3), and NFYA (nuclear transcription factor Y)—were associated with LMNA pathogenic variants across phenotype-negative individuals, DCM, and their respective cardiomyocyte RNA expression profiles in advanced heart failure. CONCLUSIONS: Proteomic profiling in individuals with likely pathogenic/pathogenic LMNA variants illuminated integral pathways across the spectrum of LMNA DCM. These findings may help advance genotype-driven biomarker discovery and tailored therapeutic development in LMNA DCM.

28 April 2022 in Journal of Cardiac Failure
Verified
Journal Article
Closed access
DKDaniel H. Katz
Daniel H. Katz
GJGinger Jiang
Ginger Jiang
LFLaurie A. Farrell
Laurie A. Farrell
DSDongxiao Shen
Dongxiao Shen
CAChristina L. Aquilante
Christina L. Aquilante
RGRobert E. Gerszten
Robert E. Gerszten